These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 28778961)

  • 1. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
    Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses.
    Rossetti RAM; Lorenzi NPC; Yokochi K; Rosa MBSF; Benevides L; Margarido PFR; Baracat EC; Carvalho JP; Villa LL; Lepique AP
    PLoS One; 2018; 13(7):e0199034. PubMed ID: 29975708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
    Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
    Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40-activated B cells induce anti-tumor immunity in vivo.
    Wennhold K; Weber TM; Klein-Gonzalez N; Thelen M; Garcia-Marquez M; Chakupurakal G; Fiedler A; Schlösser HA; Fischer R; Theurich S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Oncotarget; 2017 Apr; 8(17):27740-27753. PubMed ID: 26934557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD40-activated B cells contribute to mesothelioma tumor regression.
    Jackaman C; Cornwall S; Graham PT; Nelson DJ
    Immunol Cell Biol; 2011 Feb; 89(2):255-67. PubMed ID: 20628372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 8. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.
    von Bergwelt-Baildon MS; Vonderheide RH; Maecker B; Hirano N; Anderson KS; Butler MO; Xia Z; Zeng WY; Wucherpfennig KW; Nadler LM; Schultze JL
    Blood; 2002 May; 99(9):3319-25. PubMed ID: 11964299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.
    Dovedi SJ; Lipowska-Bhalla G; Beers SA; Cheadle EJ; Mu L; Glennie MJ; Illidge TM; Honeychurch J
    Cancer Immunol Res; 2016 Jul; 4(7):621-630. PubMed ID: 27241845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
    Carpenter EL; Mick R; Rüter J; Vonderheide RH
    J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
    Schultze JL; Michalak S; Seamon MJ; Dranoff G; Jung K; Daley J; Delgado JC; Gribben JG; Nadler LM
    J Clin Invest; 1997 Dec; 100(11):2757-65. PubMed ID: 9389740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanism and function of CD40/CD40L engagement in the immune system.
    Elgueta R; Benson MJ; de Vries VC; Wasiuk A; Guo Y; Noelle RJ
    Immunol Rev; 2009 May; 229(1):152-72. PubMed ID: 19426221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy.
    Coughlin CM; Vance BA; Grupp SA; Vonderheide RH
    Blood; 2004 Mar; 103(6):2046-54. PubMed ID: 14630810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
    Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
    Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
    Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
    Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enterotoxins can support CAR T cells against solid tumors.
    von Scheidt B; Wang M; Oliver AJ; Chan JD; Jana MK; Ali AI; Clow F; Fraser JD; Quinn KM; Darcy PK; Kershaw MH; Slaney CY
    Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25229-25235. PubMed ID: 31767744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
    Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
    Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
    Ishihara J; Ishihara A; Potin L; Hosseinchi P; Fukunaga K; Damo M; Gajewski TF; Swartz MA; Hubbell JA
    Mol Cancer Ther; 2018 Nov; 17(11):2399-2411. PubMed ID: 30097487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.